Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis

Describe hairy cell leukemia (HCL) treatment patterns using a large, nationally representative US database. Adults newly diagnosed with HCL (1 January 2006 to 30 June 2014) with continuous health plan enrollment ≥180 days pre- and 90 days post-diagnosis were identified from the QuintilesIMS PharMetr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2017-09, Vol.6 (6), p.497-508
Main Authors: Divino, Victoria, Karve, Sudeep, Gaughan, Andrew, DeKoven, Mitch, Gao, Guozhi, Knopf, Kevin B, Lanasa, Mark C
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Cladribine - therapeutic use
Databases, Factual
Female
hairy cell leukemia
Hospitalization - statistics & numerical data
Humans
Insurance Claim Review
Leukemia, Hairy Cell - drug therapy
Male
Methotrexate - therapeutic use
Middle Aged
Pentostatin - therapeutic use
Remission Induction
Retrospective Studies
Rituximab - therapeutic use
Treatment Outcome
treatment utilization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Describe hairy cell leukemia (HCL) treatment patterns using a large, nationally representative US database. Adults newly diagnosed with HCL (1 January 2006 to 30 June 2014) with continuous health plan enrollment ≥180 days pre- and 90 days post-diagnosis were identified from the QuintilesIMS PharMetrics Plus Health Plan Claims Database. Treatment patterns by line of therapy were assessed over the variable follow-up. Among 749 HCL patients (77.4% male; mean age 55.6; mean 32.3 months follow-up), only 37.7% initiated first-line therapy during the available follow-up in a mean of 4.4 months following diagnosis; the majority (75.5%) received cladribine (mean duration 7.3 days). Thirty-eight patients (5.1%) received second-line treatment. Over 2.7 years follow-up, more than a third of patients initiated first-line therapy which appeared to provide a long-lasting response.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2017-0014